558 related articles for article (PubMed ID: 28622463)
21. Clinical use of Jak 1 inhibitors for rheumatoid arthritis.
Nash P
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii31-ii38. PubMed ID: 33950231
[TBL] [Abstract][Full Text] [Related]
22. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
Vergunst CE; Gerlag DM; von Moltke L; Karol M; Wyant T; Chi X; Matzkin E; Leach T; Tak PP
Arthritis Rheum; 2009 Dec; 60(12):3572-81. PubMed ID: 19950299
[TBL] [Abstract][Full Text] [Related]
23. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
[TBL] [Abstract][Full Text] [Related]
24. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
[TBL] [Abstract][Full Text] [Related]
26. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Kim ES; Keam SJ
Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
[TBL] [Abstract][Full Text] [Related]
27. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
29. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
Aletaha D; Westhovens R; Gaujoux-Viala C; Adami G; Matsumoto A; Bird P; Messina OD; Buch MH; Bartok B; Yin Z; Guo Y; Hendrikx T; Burmester GR
RMD Open; 2021 Aug; 7(2):. PubMed ID: 34385364
[TBL] [Abstract][Full Text] [Related]
32. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Kavanaugh A; Westhovens RR; Winthrop KL; Lee SJ; Tan Y; An D; Ye L; Sundy JS; Besuyen R; Meuleners L; Stanislavchuk M; Spindler AJ; Greenwald M; Alten R; Genovese MC
J Rheumatol; 2021 Aug; 48(8):1230-1238. PubMed ID: 33526618
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
Shimizu T; Kawashiri SY; Morimoto S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Kiya R; Sato S; Yamamoto H; Kawakami A
Trials; 2023 Mar; 24(1):161. PubMed ID: 36869356
[TBL] [Abstract][Full Text] [Related]
35. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
[TBL] [Abstract][Full Text] [Related]
36. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP
Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
[TBL] [Abstract][Full Text] [Related]
40. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
Lee YH; Song GG
Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
